171 related articles for article (PubMed ID: 25301179)
41. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J; Lipton JH; Rea D; Digumarti R; Chuah C; Nanda N; Benichou AC; Craig AR; Michallet M; Nicolini FE; Kantarjian H;
Blood; 2012 Sep; 120(13):2573-80. PubMed ID: 22896000
[TBL] [Abstract][Full Text] [Related]
42. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Morotti A; Panuzzo C; Fava C; Saglio G
Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
[TBL] [Abstract][Full Text] [Related]
43. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
44. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
45. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
[TBL] [Abstract][Full Text] [Related]
46. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
47. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
48. Omacetaxine: the FDA decision.
Berman E
Clin Adv Hematol Oncol; 2011 Jan; 9(1):57-8. PubMed ID: 21326148
[No Abstract] [Full Text] [Related]
49. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
50. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
51. Updated product label allows home administration of omacetaxine mepesuccinate.
Shen AQ; Munteanu M; Khoury HJ
Oncologist; 2014 Nov; 19(11):e14. PubMed ID: 25280490
[TBL] [Abstract][Full Text] [Related]
52. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
53. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
54. Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells.
Charaf L; Mahon FX; Lamrissi-Garcia I; Moranvillier I; Beliveau F; Cardinaud B; Dabernat S; de Verneuil H; Moreau-Gaudry F; Bedel A
Leukemia; 2017 Jan; 31(1):65-74. PubMed ID: 27220663
[TBL] [Abstract][Full Text] [Related]
55. Metabolite profiling of
Nijenhuis CM; Lucas L; Rosing H; Robertson P; Hellriegel ET; Schellens JH; Beijnen AJ
Xenobiotica; 2016 Dec; 46(12):1122-1132. PubMed ID: 26998885
[TBL] [Abstract][Full Text] [Related]
56. Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.
Morotti A; Torti D; Carra G; Panuzzo C; Crivellaro S; Taulli R; Fava C; Guerrasio A; Saglio G
Curr Drug Targets; 2017; 18(4):389-395. PubMed ID: 27291926
[TBL] [Abstract][Full Text] [Related]
57. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
58. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
59. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
60. Homoharringtonine: history, current research, and future direction.
Kantarjian HM; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien SM
Cancer; 2001 Sep; 92(6):1591-605. PubMed ID: 11745238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
